| Similar Articles |
|---|
 |
The Motley Fool
September 24, 2008
Brian Lawler |
Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.   |
The Motley Fool
September 11, 2008
Brian Lawler |
Will a Change Cure Sanofi? The drugmaker charts a different course for its future. |
The Motley Fool
January 3, 2008
Brian Orelli |
8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny. |
The Motley Fool
May 21, 2009
Brian Orelli |
If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did. |
The Motley Fool
January 19, 2010
Brian Orelli |
Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious. |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most. |
The Motley Fool
November 26, 2008
Brian Orelli |
Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better." |
The Motley Fool
March 5, 2008
Brian Orelli |
Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
September 9, 2008
Brian Orelli |
Sell Dey? Perhaps Another Day Generic-drug company Mylan decides to keep its specialty pharmaceutical subsidiary. |
The Motley Fool
June 15, 2009
Brian Orelli |
Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets. |
The Motley Fool
April 7, 2010
Brian Orelli |
Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious. |
The Motley Fool
June 25, 2009
Brian Orelli |
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
The Motley Fool
March 29, 2011
Brian Orelli |
Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate. |
The Motley Fool
May 15, 2008
Brian Orelli |
Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch. |
The Motley Fool
June 27, 2008
Brian Orelli |
Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out. |
The Motley Fool
February 7, 2007
Brian Lawler |
Mylan Adjusts to the Matrix The drugmaker got a bump from a new generic and settles in with its Matrix acquisition. Investors, take note. |
The Motley Fool
November 3, 2009
Brian Orelli |
Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call. |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
The Motley Fool
October 29, 2007
Brian Orelli |
Foolish Forecast: Tenacious Teva The generic drug maker releases earnings shortly. Here's a look at whether investors should expect a generic quarter or a blockbuster. |
The Motley Fool
November 20, 2008
Brian Orelli |
Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses. |
The Motley Fool
September 18, 2008
Brian Orelli |
Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved. |
The Motley Fool
February 21, 2008
Brian Orelli |
Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company. |
The Motley Fool
March 30, 2009
Brian Orelli |
Here's Some Cash. Go Away. Bristol-Myers Squibb has to pay $2.1 million to settle a Federal Trade Commission investigation. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
October 30, 2009
Brian Orelli |
It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts. |
BusinessWeek
February 9, 2004
Kerry Cappell |
This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
The Motley Fool
October 8, 2008
Brian Orelli |
Pfizer Rearranges the Deck Chairs A reorganization without any job cuts isn't going to make the Lipitor problem go away. |
The Motley Fool
April 10, 2007
Brian Lawler |
Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs. |
The Motley Fool
June 6, 2008
Brian Lawler |
Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects. |
The Motley Fool
December 3, 2008
Brian Orelli |
High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition. |
The Motley Fool
January 29, 2007
Brian Lawler |
The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note. |
The Motley Fool
August 17, 2011
Brian Orelli |
Generic-Drug Makers Pay for Speed Lower margins -- faster. |
The Motley Fool
January 25, 2010
Brian Orelli |
Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
The Motley Fool
August 29, 2008
Brian Orelli |
A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug. |
The Motley Fool
May 7, 2007
Brian Lawler |
Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker. |
The Motley Fool
May 18, 2010
Brian Orelli |
Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now. |
The Motley Fool
September 25, 2008
Brian Orelli |
Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play? |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
The Motley Fool
July 9, 2008
Brian Lawler |
ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin. |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
The Motley Fool
May 11, 2010
Brian Orelli |
Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40. |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
February 10, 2009
Robert Steyer |
Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition? |
